Sam is the Senior Director of Scientific Advisory Services for Charles River Laboratories. With over 25 years of academic, biotechnology and nonclinical CRO experience, Sam provides scientific and regulatory guidance in developing research strategies at all stages of drug candidate development from early discovery and target validation up to pre-approval. He leads a team of seasoned scientists with extensive regulatory and scientific experience in drug development. He has experience across a wide range of drug modalities including small and large molecules, nucleotides, and advanced therapies.
Amritha is a forward-thinking executive with 20+ years of experience in healthcare transformation specifically in the fields of cell and gene therapy (CGT) and regenerative medicine. She shapes strategies, lead organizations, and bring stakeholders together with a clear goal in mind: to deliver cutting-edge therapies and cures to people around the world. Throughout her career as an executive director and advisor—and early work delving into the research—she's recognized the need for urgency in this industry. Innovation is essential to identify, develop, and create new treatments. But innovation by itself is not enough. Speed-to-market is critical, too. Lives are on the line. It's her purpose to fast-track these therapies to patients.
Dr. Koyuncu is the Founder and CEO of Crescenta Biosciences Inc., a preclinical stage drug discovery company focused on developing novel immunometabolic modulators for age-related diseases and cancer. He is a molecular biologist & virologist with deep expertise in drug discovery. The intellectual property he developed while he was working at Princeton University formed the basis of several successful startups including Kadmon Corporation and was licensed/optioned by companies including Merck. Prior to founding Crescenta, Dr. Koyuncu served as a Co-founder and Head of Biology at Evrys Bio. He received his PhD from Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany and was a post-doctoral fellow at Princeton University.
Mr. Gordon currently serves as President and CEO of Katmai Pharmaceuticals, a CNS oncology-focused biotech founded by leading chemistry, tumor biology, and clinical researchers at UCLA. During his career, Mr. Gordon played pivotal roles in the startup and growth of four biopharmaceutical companies along with one of the leading life science industry organizations, BIOCOM California. Throughout his career he served in executive management positions responsible for planning, funding, launching, building, partnering, acquiring and exiting both VC-funded and public biotechs. These include start-up ventures that established early foundational technologies in the fields of human gene therapy, regulation of kinase and ligase gene transcription pathways, novel stem cell regenerative and biomaterial treatments, and oncogene-targeted therapeutics. He has executed a large and diverse range of equity, debt, in/out licensing, R&D partnering, and M&A transactions across major international pharmaceutical markets including the U.S., Europe, and Japan. In addition to his private sector work, Mr. Gordon co-founded and currently serves as board chairman for one of the largest life science strategic procurement organizations worldwide, Core at BIOCOM California, serving over 1,700 member companies at over 3,500 sites and generating over $850MM annual group purchasing volume.
NexCore Group is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning and managing healthcare facilities including medical office buildings, wellness facilities, ambulatory surgery centers, single and multi-specialty physician buildings, life sciences facilities, seniors housing communities and transitional rehabilitation centers. NexCore has completed $4.7 billion in healthcare real estate transactions throughout 29 states, developed and acquired over 14.3 million square feet of healthcare properties across the country and currently manages over $2.9 billion of healthcare facilities spanning 7.3 million square feet. The company has been recognized repeatedly as one of the Top Healthcare Real Estate Developers in the U.S. by Modern Healthcare and HREI.
HATCHspaces ®, LLC is a Los Angeles-based real estate development platform focused on simplifying the process of scientific innovation by creating purpose-built life sciences facilities for companies emerging from academic and incubator networks. With properties in various regional submarkets, HATCHspaces’® mission is to deliver the life science community state-of-the-art lab facilities at varying scales, allowing regions to retain early-stage bioscience and biotechnology start-ups emerging from research environments.
-1.jpg?width=300&height=77&name=InsperityLogo_HR-Difference-Tag_CMYK%20(1)-1.jpg)
Our tagline, HR that Makes a Difference™, defines what we do. It emphasizes that human resources is a key driver of growth and contributes to a business’s bottom line. This is what sets Insperity apart.
Insperity has a long history of improving the success equation of small and midsize businesses across the country – because when businesses succeed, communities prosper.
And in today’s changing business environment, it’s our privilege to take care of an organization’s most valuable asset: its people.
Do you have a great company in the bioscience or medtech industry? Do you need wet-lab and/or fabrication space to develop and test your product?
